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A B S T R A C T
It is widely recognised that type 2 diabetes (T2D) represents a major disease burden but it is only recently that its
role in neurodegeneration has attracted more attention. This research has shown that T2D is associated with
impaired cerebral health, cognitive decline and dementia. However, the impact on the brain of progressive
metabolic changes associated with the pre-clinical development of the disease is less clear. The aim of this review
is to comprehensively summarise how the emergence of risk factors and co-morbid conditions linked to the
development of T2D impact cerebral health. Particular attention is directed at characterising how normal but
elevated blood glucose levels in individuals without T2D contribute to neurodegenerative processes, and how the
main risk factors for T2D including obesity, physical activity and diet modulate these eﬀects. Where available,
evidence from the animal and human literature is contrasted, and sex diﬀerences in risk and outcomes are
highlighted.
1. Introduction
It is now widely accepted that type 2 diabetes (T2D) is associated
with impaired cerebral health and cognitive decline. A large number of
studies have shown that individuals suﬀering from T2D have higher
levels of cerebro-vascular disease, smaller total and regional brain vo-
lumes, decreased cerebral connectivity, increased beta amyloid de-
position and tau phosphoralisation, accelerated rates of cognitive de-
cline, and are at greater risk of developing dementia (Adams, 2013).
What is less clear is when, before the onset of T2D, these pathological
processes start developing, to what extent they are linked to variation in
blood glucose within the normal range in those without T2D or its pre-
clinical stage, and what are the main determinants of variability in
blood glucose levels in generally healthy individuals. The purpose of
this review is thus to examine factors associated with normal blood
glucose variability in individuals without T2D, and to contrast them
with those demonstrated in individuals with T2D, to discuss the bio-
logical mechanisms implicated in these eﬀects and how they may lead
to neurodegeneration and impaired cognition, and to identify gaps in
our understanding to guide future research.
In the following sections evidence from animal and human research
will be carefully presented. Research demonstrating the involvement of
major factors in the modulation of blood glucose levels will be critically
reviewed with a particular focus on modiﬁable lifestyle and environ-
mental factors. Findings reporting associations or causal links between
blood glucose variability, cerebral health, and cognitive function will
be scrutinised. And importantly, particular care will be taken in dis-
cussing plausible biological mechanisms linking risk factors (e.g. obe-
sity, diet, exercise) and impaired brain and cognitive function.
While this review will focus more prominently on ﬁndings across
the whole available literature, samples studied vary greatly in their
cultural, socio-demographic, health and lifestyle characteristics,
making generalisation diﬃcult. Consequently, in this review we will
also make regular reference to ﬁndings established in a single well-
characterised normative population cohort, the PATH Through Life
Study (PATH) (Anstey et al., 2012), on which we collaborate (see frame
for study description). This will allow us to summarise the eﬀects that
can be detected concurrently in a homogenous group of individuals
living in the community in a speciﬁed cultural context (see also Fig. 1 at
the end of this review which contrasts ﬁndings from the broader lit-
erature from those from the PATH study).
The PATH study
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The Personality & Total Health (PATH) Through Life project (Anstey et al., 2012) is a
large population-based longitudinal cohort study investigating ageing, health,
cognition and other individual characteristics across the lifespan. Aged 20–24,
40–44 and 60–64 years at baseline (1999–2001), 7484 participants were selected
at random from the electoral rolls of the three federal electorates that make up
the Australian Capital Territory and the neighboring town, Queanbeyan. Follow-
up occurred at four year intervals over twelve years. Four waves are complete to
date. Follow-up participation rates have been high; 90% of the full 7484 at ba-
seline at wave 2, 81% at wave 3, and 63% at wave 4. At baseline, 51% of par-
ticipants were female. Though this varies somewhat depending on individual
studies selection criteria, PATH publications have a well-balanced sex ratio.
All participants provided information on a broad range of ﬁxed and time-varying
individual characteristics in interviews. Several sub-studies with more speciﬁc
data collection were also carried out, notably the Magnetic Resonance Imaging
(MRI) sub-study, and the Health and Memory sub-study, which focused on ind-
ividuals from the oldest cohort who performed particularly poorly on selected
cognitive tests. Both of these studies involved repeated MRI and venous blood
measures in the 40 s and 60 s cohorts.
Finally, although this review is not intended to systematically describe
all aspects of the clinical development and presentation of T2D we will
ﬁrst brieﬂy summarise the main mechanisms implicated in glucose
homeostasis and the typical characteristics of the disease to provide a
broader context to the present review.
2. Type 2 diabetes (T2D)
Diabetes mellitus or type 2 diabetes is a metabolic disease which
aﬀects an estimated 400 million people worldwide (Ogurtsova et al.,
2015). Historically, it has mainly developed in adults, particularly from
midlife onwards but recently it has become more common in adoles-
cents and children (Pinhas-Hamiel and Zeitler, 2005). By 2030 it is
predicted that more than 10% of all adults will suﬀer from T2D
(Ogurtsova et al., 2015).
2.1. Genetic and environmental risk factors
The single most predictive factor of T2D is being overweight or
obese (Chen et al., 2011), particularly in early adulthood (before
40 years). Other major T2D modiﬁable risk factors include physical
inactivity, diet, smoking, hypertension, and inﬂammation. Age, sex,
family history and ethnic background are the main non-modiﬁable risk
factors. T2D incidence tends to occur earlier in life in men, and lifetime
prevalence is slightly higher in women (Kautzky-Willer et al., 2016),
possibly due to greater longevity in women (Gale and Gillespie, 2001).
The lifetime risk of developing T2D in an individual with both parents
suﬀering from T2D is 70%, and 40% if only one parent is aﬀected
(Prasad and Groop, 2015). Twin studies have shown that over long
follow-ups the heritability of T2D is high, but this substantially varies.
Concordance in mono-zygotic twins ranges between 30% to over 80%
(van Tilburg et al., 2001), and in di-zygotic twins around 40%. This
suggests a substantial environmental component. Once diagnosed, the
impacts of T2D can be successfully managed through lifestyle, phar-
macological, and dietary interventions targeted at managing healthier
glucose levels, but currently the condition cannot be cured due to the
largely irreversible physiological changes underlying the chronic in-
crease of blood glucose levels.
2.2. Peripheral and central glucose homeostasis mechanisms
In healthy individuals heightened blood glucose levels after a meal
lead to insulin secretion by pancreatic β-cells into the blood stream. In
turn, the secreted insulin binds to insulin receptors in sensitive tissues
and leads to intra-cellular glucose uptake. Tissues most sensitive to
insulin binding include the liver, pancreas, fat, and muscle with sub-
stantial binding occurring also in parts of the brain and the gastro-
intestinal tract (Watanabe et al., 1998). In contrast, decreased blood
glucose levels lead to secretion of glucagon by pancreatic α-cells, which
Risk
β cell apoptosis
Peripheral IR
Oxidative stress
Amyloid β/tau
Central IR
Poor vascular health
Micro
MechanismsPositive association
Negative association
Weak/unclear evidence
Strong evidence
Genetics
Energy
Balance
Glial cell health
Neuron count
and neurogenesis
Dendrite health
Myelination
Cognitive decline
Dementia
Alzheimer’s disease
Spatial ability 
Learning
Attention
Adiposity
PA
Poor diet
Adiposity
PA
Memory
Executive
function
Whole brain volume
Grey matter volume
Hippocampus volume
Cortex
thickness
High BGHigh BG
Adiposity
Diet
Overconsumption
Poor quality
White matter volume
T2D
Lesion burden
and recovery
Motor dexterity
T2D
Physical
Activity
MCI
Poor diet
GFI D2TGB
Low high
Glucose
CognitionBrain
Macro
PATH study
Wider literature
Risk
β cell apoptosis
Peripheral IR
Oxidative stress
Amyloid β/tau
Central IR
Poor vascular health
Micro
Mechanisms
G neticse
Energy
Balance
Glial cell health
Neuron count
and neurogenesis
Dendrite health
Myelination
Cognitive decline
Dementia
Alzheimer’s disease
Spatial ability 
Learning
Attention
Adiposity
PA
Poor diet
Adiposity
PA
Memory
Executive
function
Whole brain volume
Grey matter volume
Hippocampus volume
Cortex
thickness
High BGHigh BG
Adiposity
Diet
Overconsumption
Poor quality
White matter volume
T2D
Lesion burden
and recovery
Motor dexterity
T2D
Physical
Activity
MCI
Poor diet
GFI D2TGB
Low high
Glucose
CognitionBrain
Macro
Fig. 1. Overview of current evidence linking blood glucose and type 2 diabetes to brain and cognitive outcomes.
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stimulates the release of newly synthesised glucose into the blood
stream. Blood glucose homeostasis is also controlled centrally, pre-
dominantly by the hypothalamus, in response to leptin and insulin
signalling (Tups et al., 2017). Leptin is secreted by adipose tissue as a
proportion of body fat stores and, in normal weight individuals, sup-
presses appetite and is associated with decreased food intake and in-
creased weight loss. Beyond energy intake, leptin also regulates glucose
levels through a more acute response which involves increasing sensi-
tivity of hypothalamic neurons to insulin as well as other pathways
(Koch et al., 2010). Insulin, aside from its peripheral eﬀects, is also
implicated in glucose homeostasis through central mechanisms. Insulin
has been shown to activate some hypothalamic neurons thus leading to
suppression of hepatic glucose production through vagal innervation.
Although, as noted above this action is dependent on sensitisation of
thalamic neurons by leptin. Finally, glucose sensing neurons have been
identiﬁed in the brain, principally in the hypothalamus, and are
thought to also contribute to systemic and central glucose homeostasis
through complex molecular pathways and regulation of the activity of
the sympathetic and para-sympathetic branches of the autonomic ner-
vous system (Tups et al., 2017).
2.3. Impaired glucose homeostasis and T2D disease progression
Pre-diabetes is characterised by a progressive decrease in sensitivity
of insulin receptors (insulin resistance, IR) and a concurrent increase in
blood glucose levels. Initially, blood glucose is maintained at normal
levels through an increase in insulin production and release. However,
increasingly stressed β-cells progressively fail to respond to glucose
sensing mechanisms which leads to lower insulin secretion and, over
time, to β-cell apoptosis. The processes involved in the development of
IR and decreased insulin production are complex and include many
metabolic pathways within β-cells and in target tissues and particularly
fat and muscle (Fröjdö et al., 2009; Cerf, 2013). However, inﬂammation
and oxidative stress are thought to be the main mechanisms leading to
IR, through impairment of intra-cellular pathways, and to insulin de-
ﬁciency through damage to β-cells structure.
While peripheral mechanisms have historically been thought to be
the main contributors to the development of T2D, recently, the con-
tribution of central processes has been acknowledged (Tups et al.,
2017). While these mechanisms are complex and not fully understood
the available evidence suggests that, somewhat similar to insulin re-
sistance, excess body fat promotes heightened leptin production in
obesity, which in turn leads to inﬂammation and the development of
leptin insensitivity/resistance in thalamic neurons. This in turn impairs
glucose homeostasis by reducing central insulin action and down-
regulation of hepatic glucose production, as well as through non-insulin
dependent pathways. Similar eﬀects are also thought to impair central
sensing of glucose levels and related regulating mechanisms.
Chronically elevated blood glucose levels promote a persistent state
of low-grade systemic inﬂammation and a variety of intra-cellular
metabolic disturbances in diﬀerent tissue types which over time lead to
the development of atherosclerosis, small vessel disease (aﬀecting
particularly the kidneys and the brain), and peripheral neuropathies.
The progressive development of these co-morbidities and the onset of
IR starts well before the onset of T2D proper. While a clinical diagnosis
of T2D is deﬁned as a fasting blood glucose (FBG) level ≥126mg/dl
(7 mmol/l) or a glucose level of ≥200mg/dl (11.1 mmol/l) during an
oral glucose tolerance test (OGTT), it is preceded by pre-clinical stages
of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG)
(American Diabetes Association, 2004). IGT aﬀects approximately 7%
of all adults (Ogurtsova et al., 2015) and is deﬁned as having a FBG
level of between 140 and 199mg/dl (7.8–11mmol/l) in an OGTT. IFG
is deﬁned as a FBG level between 100 and 125mg/dl (5.6–6.9mmol/l)
and aﬀects 5–17% of children and adolescents with obesity, and be-
tween 20 and 35% of all adults (Liu et al., 2014; Chen and Yeh, 2013;
Karve and Hayward, 2010). There is also evidence that, as with T2D,
IFG prevalence is higher in men in midlife (41–64 years), but higher in
women in older age (65 years+) (Chen and Yeh, 2013).
2.4. Section summary
There are a substantial, increasing number of people with T2D
worldwide. While heritability and twin studies indicate a genetic
component, the likelihood of developing diabetes is closely tied to en-
vironmental and modiﬁable risk factors, the most predictive of which is
being overweight or obese. The development of T2D is underpinned by
irreversible physiological changes accompanying the chronic increase
of blood glucose levels: decrease in insulin sensitivity, and insulin de-
ﬁciency arising from β-cell apoptosis.
3. Blood glucose within the normal range
Fasting blood glucose levels are considered within the normal range
according to the American Diabetes Association if they are≤100mg/dl
(5.6 mmol/l). Although most research in this ﬁeld has been directed at
pre- and clinical T2D, recently it has become clearer that variability in
FBG within the normal range is clinically signiﬁcant. In the PATH
study, we were amongst the ﬁrst to show that FBG in the high end of the
accepted normal range was associated with increased brain atrophy in a
structure, the hippocampus, essential to normal memory function and
highly relevant to cognitive decline and dementia (Cherbuin et al.,
2012). We have since noted chronically elevated FBG levels within the
high end of the accepted normal range are also associated with ac-
celerated cortical thinning (Shaw et al., 2017), grey matter atrophy
(Walsh et al., 2017), and decreased cognitive performance (Mortby
et al., 2013). Others have also shown associations between chronically
elevated FBG levels, accelerated brain atrophy in ageing (Enzinger
et al., 2005), and poorer memory and executive functioning (Messier
et al., 2003).
These associations are unsurprising because the thresholds for IFG
and IGT are somewhat arbitrary. The remainder of this review will
explore how some determinants of overweight/obesity and T2D lead to
an increase in FBG levels (Fig. 2), and how this increase, even within
the normal (albeit elevated) range, has a negative impact on cerebral
and cognitive health (Figs. 3–5). The eﬀects of elevated FBG will be
contrasted to those of pre- and clinical T2D.
4. Adiposity and blood glucose
Approximately 30% of the world adult population is overweight or
obese (World Health Organisation, 2015). In developed countries the
proportion is much higher and ranges from 45% in Eastern
Fig. 2. Major risk factors, pathological mechanisms, and their impact on blood
glucose metabolism. Note. Figure depicts a schematic overview of the major
modiﬁable and non-modiﬁable risk factors and impaired glucose metabolism.
N. Cherbuin and E.I. Walsh Frontiers in Neuroendocrinology 54 (2019) 100769
3
Mediterranean countries to 50–60% in Europe and the Americas
(Yatsuya et al., 2014). Of critical importance, obesity is a strong pre-
dictor of future obesity (Simmonds et al., 2016). As in adults, almost all
child cases of T2D are attributable to the “paediatric obesity epidemic”
(Ludwig and Ebbeling, 2001). Children with obesity are at a ﬁve-fold
risk of being obese in adulthood, and 70% of adolescents with obesity
remain obese until after the age of 30 (Simmonds et al., 2016). In the
PATH study, obesity in mid- and late life typically increases with as few
as 4% of participants exhibiting stable weight or weight loss (Walsh
et al., 2018). Surprisingly, the association between body mass index
(BMI; normal: 18.5–24.9; overweight: 25–29.9; obese: 30+) and FBG
has not been extensively or systematically reported in the literature.
The available evidence suggests that it is modulated by age and sex.
There is no clear association between BMI (standardized for age and
sex) and FBG in children (Mehdad et al., 2012). In contrast, in generally
healthy young adults correlations ranging from 0.38 (24.5 years, 40%
female) (Innocent et al., 2013) to 0.40 (18–22 years, 44% female)
(Farah et al., 2015) have been reported (without adjustment) and
suggest that the relationship may be stronger in females. In midlife
adults (40 years, 53% female) a correlation of 0.25 after adjustment for
age has been reported which diﬀers little between sexes or ethnicity
(White/African American) (Shen et al., 2006). In the PATH study, we
found that in participants spanning mid-life to old age (aged
45–78 years, 50% female) every one BMI point increase above 25
(lower bound of overweight range) there was an approximate
0.05mmol/l increase in FBG. Thus, an individual with moderate obe-
sity (BMI 35) would be predicted to have a blood glucose 0.75mmol/l
higher than an individual with normal weight which is substantial as it
represents almost 30% of the normal range (3–5.6 mmol/l). This asso-
ciation varied substantially across individuals due to the individual-
level complex interplay between glucose, BMI, and factors such as
physical activity (Walsh et al., 2018), and the longitudinal context, such
as whether the individual was in the process of stably gaining, loosing,
or maintaining BMI (Walsh et al., 2018). Overall, the available evidence
suggests that increasing adiposity is associated with FBG and that this
association appears to increase with age, particularly in women, al-
though research to date has not fully accounted for shared eﬀects with
co-morbid conditions.
4.1. Section summary
The research to date suggests that adiposity is positively associated
with fasting glucose, and that this association becomes more pro-
nounced in later life. However, more research is required to disentangle
the association between adiposity and FBG due to the likely impact of
co-morbid conditions.
5. Diet, physical activity and adiposity
Diet and physical activity are the main determinants of adiposity.
However, in order to better understand the links between behaviours
and pathology it is not only important to identify risk factors but also to
consider the potency and time course of their eﬀect. Therefore, this
section will summarise the magnitude and characteristics of the asso-
ciations between diet, physical activity and adiposity.
5.1. Diet and adiposity
Several aspects of diet inﬂuence body weight and increase in fat
mass, with caloric intake and diet quality being the main contributors.
While short-term variability in caloric intake appears to have relatively
little impact on body weight, an imbalance between the amount of
energy consumed and expended over longer periods (on the order of
years) leads to weight gain (Hall et al., 2011; Hill et al., 2012; Wiklund,
2016). This relationship is complex, non-linear, and modulated by
many factors including age, sex, level of physical activity to name a few,
so is best explored by focussing on an individual. As an example based
on validated NIH modelling (Hall et al., 2011), an adult male aged
30 years in an oﬃce job (sitting most of the day) who exercises mod-
erately (walking, cycling once a week) and of ideal weight (e.g.
∼66 kg) for average height (175 cm, BMI 21.5) would become over-
weight (BMI≥ 25, kg) within 3 years if he consumed only 12% excess
energy (2880 kcal/day instead of the recommended 2580 kcal/day).
For a woman using similar assumptions (average height 162 cm,
56.5 kg) the excess energy required to reach overweight (65.6 kg)
Fig. 3. Relationship between body mass, caloric intake, and physical activity
over time. Note. This conceptual schematic depicts diﬀering trajectories of body
mass over time, contingent on diﬀering levels and durations of caloric intake
and amount of physical activity. Note that while physical activity (dotted vs
dashed line) has some impact on body mass, caloric intake (three groupings of
lines) has a more pronounced association with body mass index.
Fig. 4. Impact of high blood glucose and type 2 diabetes on the brain Note. This conceptual diagram summarises the key impacts of high blood glucose and type 2
diabetes on the human brain.
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would also be ∼12% above recommended energy intake (2280 kcal/
day vs 2030 kcal/day). Given a can of cola or a full milk latte contain
∼150 kcal each and a typical burger with fries∼500 kcal this scenario
is a realistic reﬂection of how small but sustained excess caloric intake
is likely to lead to weight gain.
Diet quality is also important. Poorer diet quality is associated with
weight gain, and becoming overweight or obese in adults and children
(Aljadani et al., 2015; Hu et al., 2016), with a stronger association in
men than women. Poor diet quality is jointly associated with both
higher BMI and insulin resistance, further emphasising the close link
between energy balance and glucose metabolism (Langsetmo et al.,
2016). However it should be noted these ﬁndings are signiﬁcantly in-
ﬂuenced by the type of instrument used to assess diet (Asghari et al.,
2017). It is also noteworthy that the eﬀect of diet on weight gain appear
to be mediated at least in part by central mechanisms. In animal
models, high-fat diet is associated with inﬂammation in the hypotha-
lamus which is detectable as early as 1 day after the start of high-fat
feeding (Thaler et al., 2012) and may be a causative mechanism un-
derlying the development of obesity by promoting insulin and leptin
insensitivity (Tups et al., 2017).
5.2. Physical activity and adiposity
The relationship between physical activity and adiposity is complex
and not fully understood. Physical activity directly inﬂuences the en-
ergy balance between intake and expenditure. While it appears that
physical activity has decreased by around 100 kcal/day in the last
50 years, dietary energy intake has increased by 500 kcal/day, an
amount of energy equivalent to a typical burger and fries, between the
1970s and 2000s (Wiklund, 2016). In a population of young US adults
(21–35 years) the threshold to achieve energy balance was estimated at
7116 steps/day (Shook et al., 2015). This suggests that physical activity
may not play the most central role in the energy imbalance, and con-
comitant increased obesity prevalence observed in the population.
Nevertheless, physical activity modulates adipose tissue metabolism
beyond increased energy expenditure through potent biological me-
chanisms including oxidative stress, inﬂammation, cardio-vascular
health, and modulation of food appetite. Nevertheless, those who ex-
ercise more are more likely to maintain a normal weight or to gain less
weight, as demonstrated in both large population samples and twin
studies with twins who have discordant levels of physical activity (Ball
et al., 2001; Schmitz et al., 2000; Leskinen and Kujala, 2015; Leskinen
et al., 2005).
5.2.1. Section summary
Diet, physical activity and adiposity contribute together to energy
balance. Overall, the evidence indicates that sustained excess energy
intake is the primary driver of overweight and obesity, and accordingly
that diet quality and quantity has a greater impact on adiposity than
physical activity. Nonetheless, physical activity is associated with im-
mediate and prospective beneﬁts in weight maintenance.
6. Diet, physical activity and blood glucose
Since dietary intake, and insuﬃcient physical activity are the main
determinants of adiposity, they are also associated with blood glucose
levels before the clinical emergence of T2D. If salient, this would sup-
port the view that pathological processes leading to T2D follow a slow
gradual progression, and that between-individual variability in blood
glucose levels even within the higher end of the normal FBG range are
clinically meaningful. Therefore, this section will summarise the mag-
nitude and characteristics of the associations found between diet,
physical activity and elevated FBG at the higher end of the accepted
normal range and in T2D.
6.1. Diet and blood glucose
There is a clear association between diet and short-term blood
glucose levels. Intake of foods with higher glycaemic indexes (GI; e.g.
simple sugars, reﬁned foods, fats) lead to higher blood sugar levels than
low GI foods in randomised controlled trials both in healthy individuals
and in people with diabetes (Kaur et al., 2015; Kaur et al., 2016;
Augustin et al., 2015). Similar ﬁndings were also reported for foods
containing less ﬁbre, more proteins, more saturated fats, as well as
foods containing lower beneﬁcial phytochemicals typically found in
nuts, berries, chocolate and tea/coﬀee (Russell et al., 2016). Im-
portantly, these eﬀects have been demonstrated to have a long lasting
impact with diets of poorer quality and higher GI leading to poorer
glucose control and higher risk of insulin resistance and T2D over time
(Russell et al., 2016; Nansel et al., 2016). Our own research in the older
cohort of the PATH study (n=208, aged 60–65, 48% female) showed
that, although poorer quality diets are generally associated with higher
energy intake, the association between poor diet quality, elevated
glucose levels, and risk of incident T2D remains signiﬁcant when total
energy intake is taken into account (Walsh et al., 2017). This is im-
portant because it supports the notion of a central eﬀect of diet quality
whereby, as noted above, diets high in saturated fats and low in anti-
oxidant contribute to thalamic inﬂammation, central insulin and leptin
resistance, and lead to impaired glucose homeostasis and higher FBG
(Tups et al., 2017).
6.2. Physical activity and blood glucose
In children, objectively measured physical activity has been found
to be associated with insulin resistance at age 8 and 12 years, although
not with fasting blood glucose levels (Huus et al., 2016). The same
Fig. 5. The impact and interplay between
mechanisms underlying the detrimental
impact of high blood glucose and type 2
diabetes on the brain Note. Numbers and
colours denote associations between biolo-
gical mechanisms (listed across the bottom
of the ﬁgure) and speciﬁc impacts (depicted
by images and titles across the top of the
ﬁgure).
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pattern of low physical activity resulting in obesity and T2D is seen in
children, however the thresholds of the activity required vary sub-
stantially throughout childhood due to rapid physical growth (Ebbeling
et al., 2002). Large systematic reviews in adults shows similar asso-
ciations (Way et al., 2016; Yates et al., 2015; Yu et al., 2015). In ad-
dition, a study of generally healthy twins (50–74 years) who had been
discordant for physical activity for at least 32 years showed that the
more active twin had on average a fasting blood glucose levels
0.5 mmol/l lower than the less active twin (average diﬀerence in phy-
sical activity between twins∼ 35 MET/hour/week) (Leskinen et al.,
2013). Consistent with these ﬁndings, lack of physical activity in a large
cohort (n=28,946) was associated with a 29% increased risk of having
T2D, while a recent meta-analysis found that those who exercised
150min/week (11.25 MET/hour/week) were at a 26% decreased risk
of incident T2D (Smith et al., 2016). While the impact of physical ac-
tivity on adiposity is less pronounced than that of diet, longitudinal
evaluation of the older cohorts of the PATH study (n=716, 50% fe-
male) suggested the most sedentary individuals (undertaking<16.5
MET/hour/week, falling short of WHO recommendations for an ideal
20–30 METs/week) may experience a 1mmol/L higher FBG compared
with their more active contemporaries over three years (Walsh et al.,
2018).
6.3. Section summary
Both diet and physical activity have an impact on pre-clinical FBG
levels, and subsequent T2D incidence. Even when total energy intake is
taken into account, poor quality and high GI diet are predictive of in-
cident T2D. Physical activity above approximately 11 MET/hour/week
has a protective eﬀect.
7. Blood glucose and brain
Strong evidence showing an association between the clinical de-
velopment of T2D and impairment of brain structure and function is
available. It would therefore be expected that the early stages of the
pathological processes leading to T2D (i.e., elevated blood glucose le-
vels, insulin resistance, impaired fasting glucose), as well as T2D’s main
risk factors (i.e. obesity, diet, sedentary lifestyle) would also be linked
to poorer cerebral health. In this section, we will review the micro-
scopic and macroscopic changes in brain structure and function attri-
butable to T2D’s pathological progression while attempting to separate
those diﬀerences clearly present in the clinical stages from those linked
to the development of risk factors and the pre-clinical symptomatology.
Animal models of T2D
The goal of animal models is to parallel T2D in humans via the disruption of insulin
metabolism, presence of hyperglycemia, and often (but not always) co-morbid
factors including obesity and cardiovascular disease. T2D animal models can be
grouped in three broad categories including genetic, chemically-induced, diet
induced or a combination of these. Rodent models are most widely used due to
their shorter lifespan, ease of genetic manipulation, and easy housing. Although,
larger mammals whose physiopathology is more closely related to that of humans
have also been studied (Bellinger et al., 2006; De Koning et al., 1993; Henson and
O'Brien, 2006; Wagner et al., 2006).
Genetic models have been used to explore beta cell function, beta cell survival, and
the eﬀects of hyperglycaemia (Cefalu, 2006; Špolcová et al., 2014; Yamauchi
et al., 2002). A major limitation of these models is that it is not clear whether the
genetic variations underlying them and the associated phenotype is comparable
to the human physiopathology of T2D. Although at least for the most commonly
used genetic models which involves impaired leptin signaling, over-eating and
subsequent obesity, a common disease pathway shared with the human form of
the disease is clearly identiﬁed (Cefalu, 2006; Lönnqvist et al., 1995).
T2D can also be induced via diet, chemicals, or a combination of both. High fat
feeding, where dietary calories from fat is raised from the typical ∼10% to
∼60% or over, mirrors the pathway of weight gain, decreased beta cell function,
and impaired glucose tolerance seen in humans (Cefalu, 2006). Dietary manip-
ulation is eﬀective in inducing obesity and insulin resistance in animal models
prone to weight gain, but in many instances simultaneous genetic or chemical
manipulation is required. For example, the same high-fat diet produces clearer
hyperglycaemic eﬀects in C57BL/6J mice than A/J mice (Surwit et al., 1988),
and low-dose streptozotocin in combination with a high fat and simple carbo-
hydrate diet produces clearer diabetes-like complications than high fat diet alone
(Surwit et al., 1988) (see (Tripathi and Verma, 2014) for a review).
It is important to note that some animal models involve marked sex diﬀerences in
diabetogenic responses (King, 2012), and it is common for animal studies to be
constrained to a single sex, most often, male. Consequently, it is particularly
important to consider the implications of these methodological approaches when
evaluating the animal evidence aimed at shedding light on the eﬀects of abno-
rmal glucose metabolism.
7.1. Microscopic brain changes
Animal models of T2D have demonstrated the emergence of a
number of consistent cellular changes in neurons and glial cells (Ho
et al., 2013). Compared to wild type rats, animals genetically prone to
developing T2D have been found to have fewer neurons (∼11%, male
sample only) (Hussain et al., 2014). Although glial count does not ap-
pear to diﬀer between T2D and wild type animals, signiﬁcant glial
activation has been demonstrated in T2D indicating increased pro-in-
ﬂammatory activity. Decreased number of neurons in T2D is also con-
sistent with insulin’s neuroprotective action. Insulin has been shown to
be anti-apoptotic and protective against oxidative stress (OS) and
amyloid beta toxicity in neurons (Ball et al., 2001; Schmitz et al., 2000).
Therefore, decreased insulin levels and decreased neuronal insulin
sensitivity are expected to lead to increased neurodegeneration. This is
demonstrated in untreated male diabetic rats who underwent an acute
hyperinsulinemic severe hypoglycemic clamp and who experienced a
15-fold increase in brain damage compared to normal rats (Reno et al.,
2013). However, diabetic rats that were intensively treated and had
nearly normalised glucose levels experienced markedly reduced neu-
ronal damage. It should also be noted that microscopic changes in T2D
are not limited to neurons or the central nervous system. In male rats,
Barrière et al. demonstrated the presence of increased demyelination in
peripheral nerves which is consistent with the development of diabetic
peripheral neuropathy in the later stages of the disease (Barrière et al.,
2018).
Impaired neuronal structure and function has also been reported in
T2D. Compared to controls, synaptic count and dendritic arborisation
has been found to be signiﬁcantly lower in a male rodent models of T2D
(Ramos-Rodriguez et al., 2017; Lietzau et al., 2016; Wang et al., 2014).
Importantly, these eﬀects were shown to become stronger in a dose-
eﬀect manner as the disease progressed, indicating they start devel-
oping in the context of elevated glucose levels. Moreover, when T2D
mice were inter-bred with mice prone to developing Alzheimer’s pa-
thology their synaptic density was further decreased, particularly close
to amyloid plaques (Ramos-Rodriguez et al., 2017).
Very few histopathological studies have investigated microscopic
brain changes in humans with T2D (Nelson et al., 2009). Most post-
mortem studies have been conducted on peripheral nerves and ganglia,
as well as on the retina. They demonstrated the presence of enlarged
dystrophic axons in the periphery, and fewer glia with smaller processes
in the retina in T2D (Lechner et al., 2017; Schroer et al., 1992). Sur-
prisingly, no corresponding studies targeting the central nervous system
(CNS) could be identiﬁed, and of the available CNS histological in-
vestigations, it would appear that the research focus has been ex-
clusively on small vessel disease, micro-infarcts and related pathology
which have all been found to be more prevalent in T2D (Nelson et al.,
2009).
Some converging evidence is however available from histological
studies investigating neuropathology in obesity. In animal experiments
(primarily in males), obesity is associated with increased intra-cellular
tau phosphorylation in neurons (Gratuze et al., 2013; Spolcova et al.,
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2014) (precursor to the development of neuroﬁbrillary tangles in AD),
decreased dendritic spines numbers, and diﬀerences in microglia mor-
phology (Hao et al., 2016; Bocarsly et al., 2015). In humans, the his-
tological evidence is very limited and contradictory. One study found a
lower neuronal counts in the frontal and temporal cortices of in-
dividuals with overweight/obesity (n= 16, 31% female) (Gómez-Apo
et al., 2017). However, another could not detect any diﬀerence (n=17,
1 female), although greater variability in neuron numbers was detected
in participants with obesity (Weise et al., 2015).
Physical activity has a positive impact on the brain microstructure.
Animals who undertake voluntary or guided exercise experience greater
neurogenesis, increased spine density and mitochondria number, and
larger dendritic trees in the medial temporal and frontal cortices as well
as in the cerebellum (Stranahan et al., 2007; Dietrich et al., 2008;
Gonzalez-Burgos et al., 2011). Importantly, in a mice model of T2D in
which a decrease in hippocampal dendritic spine density was observed,
the implementation of a caloric restriction diet and voluntary exercise
on a running wheel led to an increase in spine density (Stranahan et al.,
2009). This suggests that some of the microscopic brain changes asso-
ciated with T2D can be at least in part reversed through dietary and
exercise interventions.
The extent to which variability in blood glucose levels in the ab-
sence of T2D impact the brain microstructure is less clear. Some evi-
dence suggestive of an eﬀect has been demonstrated in the context of a
caloric restriction diet. Male mice undergoing such a diet have lower
blood glucose levels (∼20–30%) than mice eating ad libitum, with this
eﬀect persisting into old age (Guo et al., 2015). Moreover, male mice on
a caloric restriction diet have been found to have better white matter
ﬁbre integrity as assessed by diﬀusion tensor imaging (DTI), and in-
creased neurogenesis (Guo et al., 2015; Lee et al., 2002). Consistent
ﬁndings were also reported in humans. For example, in the Fra-
mingham Heart Study (n=4095; 19–72 years) increasing fasting blood
glucose levels were associated with a lower measure of integrity in
white matter tracts (fractional anisotropy) (Weinstein et al., 2015).
While it is possible that these ﬁndings were in part driven by partici-
pants with T2D, it is unlikely to be limited to this group since they only
composed 3% of this sample.
7.2. Macroscopic brain changes
7.2.1. T2D
There is extensive evidence of macroscopic diﬀerences associated
with T2D. In animal models, volumetric diﬀerences have been identi-
ﬁed for the frontal cortex, hypothalamus and hippocampus, with cor-
tical volumes decreasing by approximately 19% following streptozo-
tocin-induction of T2D in rats (Wang et al., 2014). These volumetric
diﬀerences are linked to inﬂammatory pathways, and related increase
vulnerability to cerebro-vascular damage; hypoinsulinemic diabetes in
APP/PS1-STZ mouse models is associated with an increase in toxic Aβ,
phosphorilated-tau, systemic low-grade inﬂammation, and higher rate
of spontaneous haemorrhaging in the brain (Baluchnejadmojarad et al.,
2017). Interestingly, there is some animal evidence that pre-clinical
high FBG can also have macroscopic impacts on brain volume; hy-
perglycaemia is associated with accelerated cerebral atrophy in grey
mouse lemurs (Djelti et al., 2017), insulin insensitivity is associated
with lower frontal grey matter volume in rhesus monkeys (Willette
et al., 2012).
Similar diﬀerences have been reported in humans. T2D-related
atrophy has been mainly found in relation to cortical and sub-cortical
grey matter, but some ﬁndings are also available for global cerebral and
white matter atrophy, as well as sulcal widening (van Harten et al.,
2006). A recent systematic review and meta-analysis of existing studies
found that on average T2D was associated with 2% lower brain volumes
(Zhang et al., 2019). However, there was an insuﬃcient number of
longitudinal studies to determine conclusively whether the annual rate
of global or regional atrophy was greater in T2D. Importantly, another
study (Bryan et al., 2014) (n= 614) surveying exclusively T2D patients
found that disease duration was associated with grey matter atrophy
with every additional 10 years in duration being associated with a 1%
decrease in total grey matter volume. Similar ﬁndings were reported by
Saczynski et al. (n= 489) not only for grey matter but also for white
matter, white matter lesions, and infarcts volumes (Saczynski et al.,
2009) as well as by Tiehuis et al. (n=151) for total brain atrophy
(Tiehuis et al., 2008).
The PATH study, in individuals in their early 60s, demonstrates that
these eﬀects can be found concurrently in the same population. On
average individuals with T2D had 2% lower total brain volume, and 1%
lower total grey matter volume, 3% lower white matter volume (Walsh
et al., 2017), signiﬁcantly thinner cortices (mean thickness 2.27mm vs
NFG 2.32mm), but experienced a slower rate of subsequent atrophy
over twelve years (annualised percentage atrophy 0.33% vs NFG
−0.38) (Shaw et al., 2017). Further, focussing on sub-structures, par-
ticipants with T2D also had a 5% smaller thalamus, 12 smaller corpus
callosum (Walsh et al., 2019); diﬀerently shaped hippocampi, caudate,
putamen and globus pallidus, with voxel-wise shape comparison
broadly indicating inward deformations consistent with volumetric
diﬀerences (Zhang et al., 2016).
A greater number of studies investigated associations between white
matter lesions or lacunar infarcts and T2D. However, there was a high
heterogeneity in the type of populations studied (vascular, general, out-
patients) and in the type of measures considered. Overall, the evidence
was stronger for lacunar infarcts with T2D being associated with
30–130% increased risk of presence of lacunar infarcts (van Harten
et al., 2006).
In addition, the systematic review (van Harten et al., 2006) dis-
cussed above suggests that a greater number of studies investigating
associations between white matter lesions or lacunar infarcts and T2D
are available than for cerebral atrophy. However, it also points to
substantial heterogeneity between studies in the type of populations
investigated (vascular, general, out-patients) and in the type of mea-
sures considered. Overall, the evidence appears stronger for lacunar
infarcts than for brain atrophy with T2D being associated with
30–130% increased risk of lacunar infarcts (van Harten et al., 2006).
Although these associations appear more prevalent for symptomatic
than for asymptomatic lacunar infarcts. In the PATH study, T2D was not
associated with a greater prevalence of white matter lesions (white
matter hyper-intensities) observed on T1-weighted MRI scans at base-
line (age 60–64 years) (Kumar et al., 2008).
7.2.2. Fasting blood glucose
Consistent with the above ﬁndings, higher fasting blood glucose
levels have also been found to be associated with lower grey matter
volume in T2D. For example, Bryan et al. reported that every additional
10mg/dl in FBG (0.56 mmol/l; n= 614) was associated with a 0.5%
decrease in grey matter volume (Bryan et al., 2014). Similarly, Tiehuis
et al. reported that total brain volume was negatively associated with
both FBG levels (0.12% per mmol/L; 2.16% per mg/dl) and disease
duration (0.05% per year) in T2D patients (n=151, 61.5 years)
(Tiehuis et al., 2008). In addition, Weinstein et al. found, in a relatively
young cohort (n= 1597, 40.3 years), that FBG levels were negatively
associated with regional grey matter volumes (independently of the
eﬀect of T2D which was only 2.1% in this sample) in the occipital and
temporal lobes as well as with larger white matter hyperintensities
volume, and lower white matter integrity (FA) (Weinstein et al., 2015).
Consistent results were also reported in a large Japanese cross-sectional
study (n=1151, 62.6 years), in which elevated FBG was associated
with an 86% increased risk of silent brain lesions (greater than3mm)
and a 153% increased risk of peri-ventricular white matter hyper-
intensities (Bokura et al., 2008). Critically, recent evidence from a
clinical trial contrasting standard vs intensive glycemic treatment
showed that those who were more aggressively treated experienced
lower grey matter atrophy over a 40-month follow-up (Erus et al.,
N. Cherbuin and E.I. Walsh Frontiers in Neuroendocrinology 54 (2019) 100769
7
2015). These ﬁndings appear to support the view that a substantial part
of the brain atrophy detected in T2D is due to high glucose levels rather
than other aspects of the pathophysiology of the disease.
However, very few studies have investigated the question of whe-
ther variability in FBG levels within the normal range is associated with
brain structure. Using data from the PATH study, we were the ﬁrst to
systematically investigate such an association in a large cohort of
community-living individuals. Indeed, we found that in individuals
without diabetes (n=249, 62.6 years) higher normal FBG was asso-
ciated with greater hippocampal and amygdalar atrophy and explained
6–10% in volume change over 4 years (Cherbuin et al., 2012). More-
over, follow-up investigations on the same sample showed consistent
associations in other brain regions. At ﬁrst assessment, higher FBG was
associated with striatal diﬀerences particularly in the caudate and pu-
tamen (Zhang et al., 2016). In addition, longitudinal analyses con-
ﬁrmed this association but more so in those with T2D. Moreover, at
second assessment when participants were aged 68–73 years, FBG at
the high end of the accepted normal range was also associated with
lower regional brain volume in the middle and inferior frontal gyri
(Mortby et al., 2013). Analyses over 12 years of follow-up indicated that
an increase of 1mmol/l (18mg/dl) in FBG above 5mmol/l (90mg/dl)
was associated with a 10–13% increased rate of cortical thinning in the
insula, as well as posterior cingulate, parahippocampal and medial
orbitofrontal cortex (Shaw et al., 2017). Concurrently, an association
between glucose and total brain atrophy was also detected with each
additional 1mmol/l (18mg/dl) being associated with approximately
half a millilitre additional atrophy per year (0.14%/mmol/l/year or
2.5%/mg/dl/year) (Walsh et al., 2018). In a more recent exploration,
when T2D status, demographic, and lifestyle factors were controlled
for, we found each 1mmol/l (18 mg/dl) of glucose was consistently,
but not signiﬁcantly (likely due to shared variance with BMI), asso-
ciated with lower brain volumes (1.314ml lower total brain volume,
1.516ml lower grey matter volume, 0.030ml lower thalamus volume,
0.034ml lower white matter volume and 0.012ml corpus callosum
volume) (Walsh et al., 2019).
7.3. Metabolic and functional brain changes
7.3.1. T2D
T2D is associated with decreased blood ﬂow and increased cere-
brovascular resistance (Pruzin et al., 2018; Novak et al., 2006). This
contributes to a higher prevalence of small vessel disease, deep white
matter lesions, infarcts, atherosclerosis and related pathology in T2D
than NFG (Nelson et al., 2009; Ryan et al., 2014; Biessels and Reijmer,
2014). It follows that T2D is also associated with greater damage and
poorer neurovascular recovery following neurological insults such as
stroke in animals (Zhang et al., 2016) and humans (both children aged
16 or less (Michaud et al., 1991), and adults (Pruzin et al., 2018; He
et al., 2017). PET studies indicate that insulin resistance in T2D is as-
sociated with impaired cerebral glucose metabolic rate, especially in
the parietal and prefrontal cortices (Baker et al., 2011), and that this is
linked to amyloid deposition in these same areas (Willette et al., 2015).
7.3.2. Fasting blood glucose
Animal models demonstrate a link between glucose phosphorylation
and cerebral blood ﬂow. Acute changes to FBG induced by fasting can
increase cerebral blood ﬂow, particularly in the cortex and cerebellum
(Cremer et al., 1983). In humans, cerebral bloodﬂow in individuals
with IFG has been found to decrease at a signiﬁcantly faster rate than in
NFG in some regions (frontal, parietal, and temporal cortices), while it
increases at a signiﬁcantly faster rate in others (frontal, temporal, and
precentral gyri) (Thambisetty et al., 2013). The link between high FBG
and stroke prognosis is confounded by stress-induced hyperglycemia
that can be induced by the strokes, though FBG of 6.1mmol/L (110 mg/
dl) and over at the time of hospital admission in individuals without
diabetes has been associated with higher mortality and poorer
functional recovery following ischemic stroke (Capes et al., 2001). Si-
milarly to T2D, there is PET evidence that insulin resistance in NFG and
IFG is associated with lower cerebral glucose metabolism across large
portions of the frontal, lateral parietal, lateral temporal, and medial
temporal lobes (Willette et al., 2015).
8. T2D risk factors
8.1. Diet
There is good evidence in the animal and human literature in-
dicating that diet energy content and quality are associated with both
glucose metabolism and cerebral structure. Animal studies have shown
that diets lower in energy content and/or of higher quality (mostly
lower in fat and sugar) are associated with larger brain volumes, better
white matter integrity, and better cerebral health (Kanoski et al., 2010;
Casadesus et al., 2002; Titova et al., 2013). The human literature is
more sparse, and less consistent. The Mediterranean-style diet has re-
ceived most attention and while some studies have found positive cross-
sectional associations between higher adherence to the Mediterranean
diet and larger brain volumes (van Harten et al., 2006; Gu et al., 2015),
cortical thickness (Staubo et al., 2017), cerebral connectivity (Pelletier
et al., 2015), or fewer white matter lesions (Scarmeas et al., 2011;
Gardener et al., 2012), other studies failed to replicate these ﬁndings
(Luciano et al., 2017). Only one study reporting longitudinal associa-
tions has been identiﬁed. Luciano et al. showed in a large neuroimaging
sample (n= 398, 70 years) that higher Mediterranean diet adherence
was associated with less brain shrinkage over 3 years (Luciano et al.,
2017). In addition, some evidence indicating that higher meat, carbo-
hydrate and sugars and lower ﬁsh and vegetables intake is associated
with lower brain volumes (Gu et al., 2015) and cortical thickness
(Staubo et al., 2017).
8.2. Obesity
Because obesity and T2D are highly co-morbid and rely on over-
lapping mechanisms, such as leptin deﬁciency and insulin insensitivity
(e.g. ob/ob mouse and Zucker obese rat models (Cefalu, 2006)), there is
substantial overlap in animal models used to explore the impact of T2D
and obesity on the brain. Some evidence which distinguishes the impact
of obesity from that of T2D comes from a small literature exploring the
impact of obesity acutely induced by overfeeding. Overfeeding-induced
obesity has been associated with decreased blood ﬂow in the prefrontal
cortices in minipigs (Val-Laillet et al., 2011), depression-like upregu-
lation of pCREB in the striatum and hypothalamic dysfunction (Sharma
and Fulton, 2013) and deﬁcits in leptin sensitivity in the arcuate nu-
cleus in mice (Münzberg et al., 2004). Obesity following high-fat diets
in particular were linked with chronic inﬂammation and impaired
cognition in mice (Pistell et al., 2010).
The evidence linking adiposity/obesity to brain structure in humans
is somewhat limited, mostly cross-sectional, and based on hetero-
geneous adiposity measures. However, a recent review concluded that
higher adiposity may be associated with frontal lower gray matter vo-
lumes across all ages and lower parietal and temporal gray matter
atrophy in middle- and old-age, while the white matter appears to be
largely spared (Willette and Kapogiannis, 2015). Notably this occurs
even in adolescence, with comorbid obesity and T2D associated with
higher rates of cerebral atrophy, and reduced hippocampal and pre-
frontal cortex volumes (Bruehl et al., 2011). In the PATH study, we
found that higher adiposity in older age was signiﬁcantly associated
with accelerated cortical atrophy, in particular thinning in the posterior
cingulate cortex (n=404, age= 40–44 (Shaw et al., 2017), and lower
hippocampal volume (n=266, age= 60–64 (Cherbuin et al., 2012).
Further, we found a combination of high BMI and high blood glucose
was particularly detrimental to total brain and thalamus volume (Walsh
et al., 2019).
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8.3. Exercise
The evidence linking physical activity with cerebral health is strong.
In rodents, voluntary and forced exercise has been shown to be asso-
ciated with angiogenesis (Swain et al., 2003), synaptogenesis and
neurogenesis (primarily in the hippocampus, primarily involving BDNF
and IGF-1) (Nokia et al., 2016; Van Praag et al., 1999; Redila and
Christie, 2006; Voss et al., 2011), larger hippocampal volumes (Voss
et al., 2013), smaller infarctions (Ang et al., 2003) and less oxidative
damage and inﬂammation following ischemic stroke (Austin et al.,
2014; Li et al., 2004). There is also evidence that exercise is protective
against neurodegenerative conditions such as Parkinson’s disease
(Smith and Zigmond, 2003), and the neuropathology and cognitive
indicators of Dementia (Tapia-Rojas et al., 2016; Ahlskog et al., 2011).
These beneﬁcial eﬀects are linked to reduced inﬂammation (Ryan and
Nolan, 2016) and higher BDNF levels (Bechara and Kelly, 2013; Ang
et al., 2003) and related neurogenesis and energy homeostasis (Marosi
and Mattson, 2014; Vaynman et al., 2006).
Consistent ﬁndings have been demonstrated in humans (Voss et al.,
2013). Direct observation of synaptogenesis in humans due to exercise
is diﬃcult to obtain, but its occurrence is supported by convergent
evidence of exercise-related upregulation of neurotrophic factors mea-
sured peripherally (Voss et al., 2011; Vega et al., 2006; Nybo et al.,
2002), increased gene expression associated with neuroplasticity
(Cotman and Berchtold, 2002), and improved prognosis following is-
chemic stroke (Gordon et al., 2004). Multiple studies note a positive
association between physical exercise and cortical thickness (Rogge
et al., 2018), larger grey and white matter volume, particularly in the
prefrontal cortex (Voss et al., 2011; Colcombe et al., 2006) and hip-
pocampus (Erickson et al., 2011; Kleemeyer et al., 2016). The positive
association between physical exercise and brain volume is more pro-
nounced in older adults, suggesting it plays a role in slowing age-as-
sociated atrophy (Colcombe et al., 2006), and can be helpful in pre-
serving function in cases of neurodegenerative disease such as dementia
(Heyn et al., 2004). The major pathways mediating the beneﬁcial ef-
fects of exercise on the brain are through managing other risk factors
such as adiposity, T2D, and atherosclerosis (Ahlskog et al., 2011; Stults-
Kolehmainen, 2013; Heyn et al., 2004), release of neurotrophins (Voss
et al., 2013) and reduction of neural inﬂammation (Ryan and Nolan,
2016), and promoting blood ﬂow via cardiorespiratory ﬁtness (Rogge
et al., 2018; Burns et al., 2008).
8.4. Section summary
Together these ﬁndings suggest that widespread brain atrophy and
white matter lesions are more prevalent in T2D and that increased FBG
is associated with higher atrophy not only in T2D but also in normal
older adults with higher FBG levels within the normal range.
Importantly, these eﬀects appear to start developing and be detectable
in middle-age, before 60 years, and increase with disease duration.
9. Blood glucose and cognition
9.1. T2d
In animal models, T2D typically induced through a high fat diet
and/or by injection of streptozotocin leading to a sustained increase in
blood glucose and body weight has been linked to poorer episodic,
working, and spatial memory (object recognition, Morris maze, and Y
maze tasks) (Noor and Zahid, 2017; Carvalho et al., 2013), and learning
(lever-press task) (Moreira et al., 2007). Several studies note that the
neurocognitive deﬁcits seen in these T2D animal models mirror those
seen in dementia (Carvalho et al., 2013).
In humans strong and consistent evidence shows that T2D is asso-
ciated with an increased risk of cognitive decline and dementia. A re-
cent meta-analysis (Adams, 2013) summarising ﬁndings from 14 studies
and more than 2 million individuals demonstrates that T2D is asso-
ciated with 60% increased risk of dementia. Interestingly, this eﬀect is
overall somewhat greater (4%) in women than men, and stronger for
vascular (women: RR 2.34; men: RR 1.73) than for non-vascular de-
mentia (women: RR 1.53; men: RR 1.49). Another large meta-analysis
also indicates that a higher risk of AD is associated with T2D according
to ethnicity (Western: RR 1.36; Eastern: RR 1.53) (Zhang et al., 2017).
Moreover, a previous meta-analysis found that T2D was associated with
a 20% increased risk of Mild Cognitive Impairment (MCI), the pre-
clinical stage to dementia (Cheng et al., 2012).
Of critical importance is that T2D does not only have a distal risk for
cognitive function (i.e. for dementia) but is linked to impairment along
the disease process with symptoms being present before or developing
soon after clinical diagnosis. Meta-analyses of the available literature
show that T2D is associated with lower performance in motor function,
episodic and logical memory, verbal ﬂuency, cognitive ﬂexibility, at-
tention and processing speed (Monette et al., 2014; Sadanand et al.,
2016; Palta et al., 2014). This is also observed in the PATH data, where
we found that T2D was associated with signiﬁcantly poorer perfor-
mance on a measure of ﬁne motor dexterity (the Purdue pegboard test
(Zhang et al., 2018), alongside higher total brain atrophy (n=478, age
60–64 (Kumar et al., 2008), and lower striatal volume (n= 271, age
60–64 (Zhang et al., 2016). Importantly, in the same cohort T2D was
also associated with an increased risk of developing mild cognitive
disorders (Cherbuin et al., 2009).
9.2. Fasting blood glucose
In addition to the cognitive impairments associated with T2D as a
whole it has also been shown that amongst individuals with T2D those
with higher FBG experience faster cognitive decline and are at higher
risk of dementia. But perhaps of greater signiﬁcance, this eﬀect does not
appear to be restricted to T2D but is also detectable in its pre-clinical
stages (IFG and IR), and within the normal FBG range in people without
T2D. For example, in a cohort of older Japanese individuals without
T2D (n=1017, 68.5 years), higher glucose levels (6.1–6.9 mmol/l) 2 h
after a glucose tolerance test compared to normal levels (< 5.6 mmol/l)
have been found to be associated with a higher risk of vascular de-
mentia (HR 1.93, 95% CI 1.03–3.61) but not AD or other dementias
(Ohara et al., 2011). In children, there is some evidence that blood
glucose is implicated in self-control (Gailliot and Baumeister, 2007),
though this is contentious (Vadillo et al., 2012). More persuasively, in a
cohort of adults without T2D (n= 41, 64.7 years) higher FBG within
the normal range (< 6.1mmol/l) was associated with slower reaction
time (Raizes et al., 2016) (each 1mmol/l increase in plasma glucose
associated with 0.05 s (2%) slower reaction time). In a third study of
individuals without T2D (n= 411, 50.6 years) higher FBG was asso-
ciated with poorer episodic memory in women but not in men
(Rolandsson et al., 2008). Finally, in a large longitudinal study
(n= 838; 63.1 years; 3.3% individuals with T2D), higher FBG was as-
sociated with greater decline in general cognition (each 1mmol/L
higher FBG=9% greater decline per year), perceptual speed (each
1mmol/L≈ 7% greater decline/year), verbal (each 1mmol/L≈ 3%
greater decline/year) and spatial abilities (each 1mmol/L≈ 6% greater
decline/year) (Seetharaman et al., 2015). Overall, these ﬁndings sug-
gest a consistent association between FBG in the high end of the ac-
cepted normal range and lower cognitive function in mid-life to early
old age in individuals free of T2D. Unfortunately, to date no meta-
analysis has been conducted to more clearly characterise the associa-
tion between FBG levels within the normal range and cognitive function
in people free of T2D and therefore caution should be exercised in in-
terpreting these ﬁndings. In the older PATH cohort (age 60–65 years),
blood glucose levels in people without T2D were associated with lower
regional volumes (grey and white matter) and corresponding cognitive
deﬁcits similar to the patterns found in the literature, notably higher
FBG (6.1mmol/L and higher) being associated with lower frontal gyri
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volumes and performance on working memory and reaction time tasks
(Mortby et al., 2013).
9.3. Risk factors
9.3.1. Obesity
A clear link has been demonstrated between mid-life obesity and the
risk of cognitive impairment later in life with individuals with obesity
being at a 60–100% increased risk of dementia (Loef and Walach, 2013;
Anstey et al., 2011). Moreover, a recent systematic review (Prickett
et al., 2015) investigating the association between obesity and cognitive
function and including 17 studies surveying individuals below the age
of 65 has found that mid-life obesity was associated with lower per-
formance in cognitive functioning, psychomotor performance and
speed, visual construction, concept formation and set shifting, and de-
cision making (but was inconclusive for visual memory, verbal
memory, complex attention, delay discounting and inhibition). Im-
portantly, this eﬀect does not seem to be limited to mid-life obesity or
late life cognition. For example, a cross-sectional study of 299 women
(18–35 years) found that being obese was associated with signiﬁcantly
lower attention scores (Cook, 2017). Moreover, a meta-analysis of
weight loss interventions in individuals with obese/overweight across
twenty studies, 13 of which were longitudinal, found that weight loss
was associated with a signiﬁcant improvement in attention and
memory (Veronese et al., 2016). Similar ﬁnding were also demon-
strated across bariatric surgery randomised controlled trials (Thiara
et al., 2017).
9.3.2. Exercise
The evidence linking physical activity and cognitive decline is
strong. Findings from systematic reviews indicate that participating in
regular exercise is associated with a 15–40% decreased risk of dementia
(Beckett et al., 2015). As for obesity, the protective eﬀect of exercise is
already detectable in relation to general cognition in non-demented
individuals. Our recent meta-analysis (Northey et al., 2018) of exercise
interventions in people over 50 years shows that regular exercise
(45–60min 2–7 days per week) at moderate to high intensity is asso-
ciated with improved cognitive function across all domains tested
(global, attention, executive, memory, working memory). In PATH,
physical activity was found to be positively associated with cognitive
performance across multiple domains, particularly in the youngest co-
hort (aged 20–25), a stable, longitudinal association (Bielak et al.,
2014).
9.3.3. Diet
Caloric overconsumption has been associated with deﬁcits in global
cognition, executive function, attention, information processing, and in
particular memory (Reichelt et al., 2018; Roberts et al., 2012;
Attuquayeﬁo and Stevenson, 2015), while caloric restriction has been
associated with preserved cognition and enhanced memory (Murphy
et al., 2014). Although evidence for other macronutrients such as pro-
tein and carbohydrate is mixed (Attuquayeﬁo and Stevenson, 2015), it
is well established that diets high in fat, particularly in tandem with
caloric overconsumption, are detrimental to cognitive health
(Attuquayeﬁo and Stevenson, 2015; Solfrizzi et al., 2017). Micro-
nutrients, chieﬂy vitamins (notably B, C, and folate) (Solfrizzi et al.,
2017; Travica et al., 2017), ﬂavonoids (Williams and Spencer, 2012),
antioxidants (particularly polyphenols (Solfrizzi et al., 2017) such as
resveratrol (Murphy et al., 2014), curcumin (Kuszewski et al., 2018)
and caﬀeine (Panza et al., 2015), and long chain polyunsaturated fatty
acids (particularly omega-3 (Murphy et al., 2014; Cutuli et al., 2016)
have been shown to beneﬁt memory, semantic ﬂuency, working
memory, executive function, and reduce risk of developing cognitive
impairment. However, it is likely these eﬀects are driven, at least in
part, by the detrimental impact of deﬁciencies, rather than surplus
consumption providing beneﬁts (Solfrizzi et al., 2017; Travica et al.,
2017).
A dietary pattern perspective places macro- and micro-nutrient in-
take in the whole dietary context. An unhealthy, ‘Western’ dietary
pattern, characterised by red meat, processed and fatty foods, has been
associated with global cognitive, and speciﬁcally visuospatial, decline
(Solfrizzi et al., 2017; Shakersain et al., 2016). Conversely, a ‘Medi-
terranean’ dietary pattern, characterised by legumes, fresh vegetables,
grains, and monounsaturated fatty acids has been associated with su-
perior cognitive function and reduced risk of cognitive decline and
developing Alzheimer’s disease (Feart et al., 2009; Lourida et al., 2013).
This has led to the development of diets designed to improve cognition
in ageing and reduce the risk of Alzheimer’s disease, such as the Med-
iterranean-DASH Intervention for Neurodegenerative Delay (MIND)
diet (Morris et al., 2015). The MIND diet has been associated with a
20% reduction in the likelihood of developing mild cognitive impair-
ment in the PATH study (n= 1228, participants aged 72–76) (Hosking
et al., 2017).
9.3.4. Section summary
High pre-clinical FBG and T2D both have a negative impact on
cognitive function in ageing. This manifests in poorer performance and
accelerated decline in measures of global cognition, more speciﬁcally
memory, and increased risk of developing dementia. Risk factors for
high FBG and T2D such as obesity, sedentary lifestyle, and poor diet are
themselves directly implicated in cognitive decline.
10. Biological mechanisms mediating risk
While the ﬁndings reviewed above provides a strong evidence base
linking increasing FBG and T2D to neurodegeneration and cognitive
decline, most of the human research is correlational and therefore
cannot address the question of causation. Although, causal links in
humans cannot be unambiguously resolved for a complex pathology
which takes years to develop and involves the interaction of several
factors, one approach to clarifying causal links is the plausible identi-
ﬁcation of biological mechanisms that are likely to explain the patho-
physiology of the disease under consideration. For this reason, this
section will brieﬂy review the main mechanisms which contribute the
eﬀect of FBG, T2D and their risk factors on cerebral and cognitive
health.
10.1. Oxidative stress
Oxidative stress (OS) is one of the main mechanisms contributing to
molecular and cellular senescence and it is also implicated in the neu-
ropathology of T2D. OS is an umbrella term used to refer to the im-
balance in production of reactive oxygen species (superoxide and hy-
drogen peroxide) as part of metabolic processes relative to the counter-
active action of anti-oxidants that are mostly produced through pro-
tective cellular mechanisms but also contributed through dietary intake
(Lugrin et al., 2014). OS is known to damage DNA, shorten telomeres
(Reichert and Stier, 2017), and degrade cellular structure and thus is
associated with increased apoptosis and impaired cellular function. In
the CNS it is also associated with decreased synapto and neuro-genesis
(Yuan et al., 2015), vascular damage (Forstermann, 2010), and in-
creased protein mis-folding leading to increased amyloid plaques and
tauopathy (Alavi Naini and Soussi-Yanicostas, 2015, 2015).
Increased OS has been shown to be increased in animal models of
T2D and to be associated with neuro-vascular damage, glial prolifera-
tion and shrunken and damaged neuronal structures (Yang et al., 2013;
Zherebitskaya et al., 2009). In humans, associations between increased
OS levels in T2D have also been reported. There is limited evidence on
the association between glucose levels and OS. However, at least in
children with type 1 diabetes, ﬂuctuation in blood glucose was found to
be associated with higher OS levels even in those with stable glycaemia
(Meng et al., 2015). Importantly, in vitro studies investigating
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variability in glucose levels compared to hyperglycaemia have sug-
gested that ﬂuctuation in glucose levels may produce more OS and be
more damaging than stably high glucose levels (Wright et al., 2006).
However, whether high glucose levels lead to increased OS or whether a
bi-directional relationship is at play is also under question since higher
OS levels appear to be associated with insulin resistance and impaired
glucose tolerance and pathological pathways linking OS to damage of
insulin producing cells has also been identiﬁed (Kopprasch et al., 2015;
Henriksen et al., 2011; Hurrle and Hsu, 2017).
10.2. Inﬂammation
Chronic inﬂammation plays a major role in the development of T2D.
Adipose tissue produces pro-inﬂammatory cytokines and overweight
and obesity have been demonstrated to lead to heightened low grade
systemic inﬂammation (Hotamisligil, 2017; Reilly and Saltiel, 2017).
Moreover, as physical activity has anti-inﬂammatory eﬀects, the se-
dentary lifestyle typically associated with the development of T2D
compounds the pro-inﬂammatory mechanisms associated with in-
creased adiposity (Pedersen, 2017). Pro-inﬂammatory cascades are
further activated through the eﬀect of poor diet and increased oxidative
stress discussed above as well as other co-morbid conditions including
depression and cardio-vascular disease (Minihane et al., 2015).
10.3. Impaired vascular health
Evidence from a recent meta-analysis indicates that chronic hy-
perglycemia is associated with increased risk of cardio-vascular disease,
coronary heart disease, stroke, and peripheral arterial disease (Zhang
et al., 2012). A number of mechanisms are thought to contribute to
these eﬀects. The increased production of OS and activation of pro-
inﬂammatory cascades associated with elevated glucose levels leads to
endothelial dysfunction (Hamilton and Watts, 2013) and vascular da-
mage (Zhang et al., 2012). Elevated glucose levels promote the pro-
duction of proteins, called advanced glycation end products, which
contribute to the formation of plaques, atherosclerosis, and ultimately
decreased blood ﬂow in all organs including the brain (Aguiar et al.,
2014). These processes progressively lead to the development of small
vessel disease, chronic cerebral hypoxia, and neuronal damage (Sims
et al., 2014; Martinez Sosa and Smith, 1979).
10.4. Impaired neurogenesis
Neurogenesis, while not widespread in the adult human brain,
contributes signiﬁcantly to hippocampal function. Brain-Derived
Neurotrophic Factor (BDNF) is a major modulator of neurogenesis with
higher levels being associated with increased production and diﬀer-
entiation of granule cells in the hippocampus. Higher blood glucose
levels have been shown to be associated with lower BDNF levels and
decreased neurogenesis (Krabbe et al., 2007). Interestingly, experi-
mentally increased BDNF levels have been shown to attenuate hy-
perglycemia in male rats which may partially explain the protective
role of exercise and environmental enrichment in protecting against
neurodegeneration in the context of metabolic disease (Meek et al.,
2013).
10.5. CNS insulin & neuronal metabolism
Closely tied to glucose metabolism, and strongly associated with
adiposity, insulin is directly implicated in cognitive performance and
decline (Ott et al., 2012; Plum et al., 2005). Peripheral insulin crosses
the blood–brain barrier (Pardridge et al., 1985) and acts upon wide-
spread neural insulin receptors which are concentrated in the olfactory
bulb, cerebellum, hypothalamus, and hippocampus (Plum et al., 2005).
Central insulin is upstream of signalling cascades implicated in synaptic
plasticity, synaptogenesis, and neurogenesis (Kleinridders et al., 2014),
and as previously noted, can be protective against OS (Augustin et al.,
2015). Insulin resistance impairs the uptake of glucose in neurons and
compromises their function. There is both observational and experi-
mental evidence showing that insulin and Insulin-like Growth Factor
(notably IGF-1 and IGF-2) can decrease the intracellular hallmarks of
AD (circulating amyloid-β and hyperphosphorylated tau (Plum et al.,
2005), although the causal association between chronic insulin re-
sistance and the development of AD remains unclear (Freiherr et al.,
2013). In both healthy and cognitively declining individuals, insulin
resistance can cause widespread dysfunction most clearly seen in the
hippocampus, and consequently memory function (Plum et al., 2005;
Convit, 2005). This has therapeutic potential - intranasal administration
of insulin is associated with acute and prologued improvements in
memory, and is therefore being pursued as a possible AD treatment (Ott
et al., 2012; Freiherr et al., 2013).
10.6. Protein mis-folding
Although protein mis-folding receives more attention in acute con-
ditions such as Alzheimer’s (amyloid plaque) and Parkinson’s (Lewy
bodies) disease it is a key ageing mechanism throughout the body and
in the brain (Basaiawmoit and Rattan, 2010). Increasing age and tissue
damage mediated by the processes discussed above are associated with
impaired clearance of the bi-products of cellular metabolism. The ac-
cumulation of these bi-products progressively compromises cellular
function and leads to further damage and increasing aggregation of mis-
folded proteins thus further impacting function.
The patho-physiology of T2D contributes to the accumulation of
mis-folded proteins in several ways. Raised OS and pro-inﬂammatory
activity associated with the development of T2D contribute to damage
of cellular mechanisms which become less eﬃcient at clearing mis-
folded proteins or in repairing DNA damage associated with protein
mis-folding. Moreover, cerebro-vascular disease is associated with de-
creased clearance of mis-folded proteins, at least in Alzheimer’s and
Parkinson’s disease, and thus leads to increased amyloid plaque and
Lewy bodies formation (Yarchoan et al., 2012; Grimmer et al., 2012;
Choi et al., 2011; van der Holst et al., 2015; Deleidi and Maetzler,
2012).
10.7. Section summary
Several concurrent biological mechanisms are associated with the
patho-physiology of high blood glucose levels and T2D. Cellular da-
mage and impaired neural function arising from an overabundance of
reactive oxygen species, a situation known as oxidative stress, is asso-
ciated bi-directionally with hyperglycaemia and T2D. Chronic in-
ﬂammation promoted by excess adiopose tissue, lack of physical ac-
tivity and poor diet further exacerbates oxidative stress and tissue
damage. Hyperglycaemia and pro-inﬂammatory processes also con-
tribute to vascular disease and have been linked with lower Brain-
Derived Neurotrophic Factor levels, thus compromising neuronal in-
tegrity and impairing neurogenesis. Disruption of central insulin func-
tion associated with T2D leads to impaired energy metabolism in
neurons and is implicated in declining cognitive performance. There is
also growing evidence that T2D is implicated in protein mis-folding,
largely via oxidative stress and inﬂammation, and thus contributes to
the development of neurodegenerative disease such as Alzheimer’s.
11. Conclusions
The notion that T2D is associated with neurodegeneration, cognitive
impairment, dementia and mortality is not new. However, these asso-
ciations are often thought to be mostly relevant in old age despite the
availability of substantial evidence indicating that the pathological
processes at play are initiated in mid-adulthood or before. The aim of
this review was therefore to comprehensively summarise the available
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research literature demonstrating a link between the early emergence
and impact of the main risk factors for T2D (obesity, physical activity,
and dietary intake), their associations with increasing FBG levels with
ageing and the progressive dysregulation of glucose metabolism, and
the impact these eﬀects have on cerebral health and cognitive function
before, during and after the clinical development of T2D. In addition, a
particular focus was on evaluating whether higher fasting blood glucose
levels within what is considered the normal range present a risk to brain
and cognitive health.
As a whole the body of evidence presented above strongly suggests
that persistently elevated FBG are associated with brain shrinkage,
progressive loss of function across several cognitive domains, the de-
velopment of dementia, and ultimately, premature death. It is also clear
that T2D’s main risk factors contribute in a major way to these eﬀects
and that clinical T2D represents the greatest risk to cerebral health.
However, while their contributions overlap, each of these components
appear to contribute separately and independently of each other to the
neurodegenerative processes leading to functional loss. Of major im-
portance is the fact that clear pathological mechanisms supporting a
causal link between glucose metabolism dysregulation and neurode-
generation have been identiﬁed.
It is of particular concern that the pathological cascade leading to
higher FBG and ultimately T2D typically begins decades before and
starts impacting cerebral health and cognition from its onset. The im-
plication of these ﬁndings is that policy responses and interventions
aimed at preserving neurocognitive capital and slowing cognitive de-
cline in ageing should be initiated as early as possible and preferably in
childhood or early adulthood and be sustained across the adult lifespan.
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